 Oncosec Medical Incorporated the Company or Oncosec Nasdaq: ONCS, a company developing late-stage intratumoral cancer immunotherapies, today announced published data in Clinical Cancer Research, linked here, that demonstrated its lead product candidate, TAVOTM interleukin-12 or IL-12 plasmid, in combination with the anti-PD-1 checkpoint inhibitor KEYTRUDA pembrolizumab, produced a 41 overall response rate ORR, with 36 complete response in a Phase 2, single arm study evaluating patients with metastatic melanoma selected to be anti-PD-1 checkpoint resistant. 